Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (51-60 of 251) with videos related to

Pageof 26
Sort By:
Cancer Research|January 28, 2004
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancerAmado J Zurita, Patricia Troncoso, Marina Cardó-Vila, et al.
Statistics in Medicine|April 12, 2007
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoringPeter F Thall, Leiko H Wooten, Christopher J Logothetis, et al.
BMC Medical Genomics|August 6, 2009
Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression dataIvan P Gorlov, Jinyoung Byun, Olga Y Gorlova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancerShi-Ming Tu, Paul Mathew, Franklin C Wong, et al.
Urologic Oncology|April 10, 2003
Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II studyJeri Kim, Randall E Millikan, Terry L Smith, et al.
Cancer|June 5, 2003
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastasesLance C Pagliaro, Ebrahim S Delpassand, Dallas Williams, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 10, 2004
Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cellsVemparala Subbarayan, Anita L Sabichi, Jeri Kim, et al.
The Prostate|June 22, 2010
Adipose tissue-derived stem cells promote prostate tumor growthLukas Prantl, Fabian Muehlberg, Nora M Navone, et al.
Cancer Informatics|May 22, 2009
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancerJing Wang, Kim Anh Do, Sijin Wen, et al.
Cancer Discovery|July 2, 2013
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerChristopher J Logothetis, Gary E Gallick, Sankar N Maity, et al.
Pageof 26

Showing results (51-60 of 251) with videos related to

Sort By:
Pageof 26
Cancer Research|January 28, 2004
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancerAmado J Zurita, Patricia Troncoso, Marina Cardó-Vila, et al.
Statistics in Medicine|April 12, 2007
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoringPeter F Thall, Leiko H Wooten, Christopher J Logothetis, et al.
BMC Medical Genomics|August 6, 2009
Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression dataIvan P Gorlov, Jinyoung Byun, Olga Y Gorlova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancerShi-Ming Tu, Paul Mathew, Franklin C Wong, et al.
Urologic Oncology|April 10, 2003
Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II studyJeri Kim, Randall E Millikan, Terry L Smith, et al.
Cancer|June 5, 2003
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastasesLance C Pagliaro, Ebrahim S Delpassand, Dallas Williams, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 10, 2004
Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cellsVemparala Subbarayan, Anita L Sabichi, Jeri Kim, et al.
The Prostate|June 22, 2010
Adipose tissue-derived stem cells promote prostate tumor growthLukas Prantl, Fabian Muehlberg, Nora M Navone, et al.
Cancer Informatics|May 22, 2009
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancerJing Wang, Kim Anh Do, Sijin Wen, et al.
Cancer Discovery|July 2, 2013
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerChristopher J Logothetis, Gary E Gallick, Sankar N Maity, et al.
Pageof 26